Connect with us

Business

RBI MPC Meeting 2025 Live Updates: RBI Cuts Repo Rate By 25 Bps, To Conduct OMO Purchases Of Govt Securities Of Rs 1 Lakh Crore

Published

on

RBI MPC Meeting 2025 Live Updates: RBI Cuts Repo Rate By 25 Bps, To Conduct OMO Purchases Of Govt Securities Of Rs 1 Lakh Crore


Shiv Garg, Director, Forteasia Realty Pvt. Ltd..

The Reserve Bank of India (RBI) has decreased the policy rate to 5.25% and made a bold statement by adopting the theme of growth support. The developers will be able to get working capital more easily, which will, in turn, make it possible for them to get their projects financed and thus, speed up the construction of townships, plotted, and large integrated projects that are heavy on capital expenditure. Lowering the monthly home loan EMI by Rs 1,850 for a 20-year Rs 35 lakh loan will make housing more affordable. It will happen at the time when banks and NBFCs are lowering their loan rates, and the developers with strong balance sheets can refinance at lower costs and pass on the benefits to the buyers in terms of limited-time offers and schemes. This policy measure, along with an upgraded FY26 GDP forecast, will usher in a new cycle of launches, the consolidation of weaker players, and increased institutional investment in residential, commercial, and warehousing assets.

Anurag Goel, Director, Goel Ganga Developments

The recent reduction of the repo rate by 25 basis points to 5.25% is expected to have a significant impact on home loan rates in the coming months, assuming banks and HFCs quickly pass the benefit on to the borrowers. Upward revision of GDP growth forecasts for FY26 leads to a better income view and increased job confidence, which is exactly what makes those who are undecided finally turn their inquiries into bookings. The combination of lower EMIs and a more optimistic growth outlook creates a perfect timing for the end-users in the affordable and mid-income segments, particularly in Tier II and III cities where EMI sensitivity is high. This act can spark a revival in the areas where the price hike was already felt, and at the same time, it would contribute to pro-cyclical and healthy upcycling rather than speculative froth.

Pramod Kumar Gupta, Director, Kadamashree Developers India LLP

The repo rate of 5.25% which came after the series of cuts in 2025, significantly boosted the relative appeal of real estate as an investment class compared to fixed-income products. Investors are likely to see Grade A residential, commercial strata units and listed REITs as the new places for superior risk-adjusted returns and regular cash flows as safer instruments yields go lower. The increased FY26 GDP growth expectancy points to a long-lasting demand situation for the likes of office, retail and logistics that will in turn support rental growth and reduced vacancy rates midterm. The policy change is like rolling out the carpet for homebuyers and investors who think long-term as it indicates the start of a friendly interest rate cycle where getting in on quality assets during the rise could provide both capital appreciation and income stability for the next 3–5 years.



Source link

Business

Anthropic officially designated a supply chain risk by Pentagon

Published

on

Anthropic officially designated a supply chain risk by Pentagon



The supply chain risk designation of the artificial intelligence firm is a first for a US company.



Source link

Continue Reading

Business

FDA official calls UniQure’s gene therapy a ‘failed’ treatment for Huntington’s disease

Published

on

FDA official calls UniQure’s gene therapy a ‘failed’ treatment for Huntington’s disease


Thomas Fuller | SOPA Images | Lightrocket | Getty Images

UniQure needs to run another study to prove that its gene therapy “actually helps people with Huntington’s disease,” a senior U.S. Food and Drug Administration official said on a call with reporters Thursday.

The official, who requested anonymity before discussing sensitive information, confirmed the agency has asked the company to run a placebo controlled trial of its treatment, which is administered directly into the brain. UniQure has said that type of study isn’t ethical because it would require putting people under general anesthesia for hours, a characterization the official disputed.

“So what is really going on? UniQure is the latest company to make a failed therapy for Huntington’s patients,” the official said. “They likely acknowledge or understand at some deep level that their trial failed years ago, and instead of doing the right thing and running the correct clinical study, UniQure is performing a distorted or manipulated comparison in the mind of FDA.”

The comments mark the latest development in a messy public spat between UniQure and the FDA, and as the agency comes under fire for a number of recent drug approval application rejections, including some where companies have accused it of going back on previous guidance. FDA Commissioner Marty Makary in an interview with CNBC’s Becky Quick last week seemingly criticized UniQure’s gene therapy for Huntington’s disease. Makary didn’t name UniQure but described its treatment.

UniQure then accused the FDA of reversing its stance that the company’s clinical trial data would be sufficient to seek approval. UniQure’s study used an outside database to measure how patients with Huntington’s disease might decline without treatment, known as an external control. UniQure has said it wouldn’t be feasible to run a true randomized, double-blind placebo-controlled study, considered the gold standard, because it wouldn’t be ethical to make people undergo a sham hours-long brain surgery.

The FDA official said the agency “never agreed to accept this distorted comparison” and the FDA “never makes such assurances.” Instead, the “FDA will always say, ‘Well, we have to see the data when we get it.'”

UniQure didn’t immediately comment.

The company’s stock rose more than 10% on Thursday and has fallen 58% this year as of Thursday afternoon.



Source link

Continue Reading

Business

US mortgage rates rise to 6% after three-week slide as oil-driven bond yields climb – The Times of India

Published

on

US mortgage rates rise to 6% after three-week slide as oil-driven bond yields climb – The Times of India


The average long-term US mortgage rate edged higher this week, ending a three-week decline as bond yields rose amid oil-price pressures linked to the war with Iran.The benchmark 30-year fixed mortgage rate increased to 6% from 5.98% last week, mortgage buyer Freddie Mac said on Thursday. A year ago, the average rate stood at 6.63%, AP reported.The modest uptick breaks a three-week slide in borrowing costs, with mortgage rates having hovered close to the 6% mark for most of this year. Last week’s average had marked the first time the rate dipped below 6% since September 2022, reaching its lowest level in nearly three and a half years.Mortgage rates are influenced by several factors, including the Federal Reserve’s interest-rate policy, investor expectations about inflation and economic growth, and movements in the bond market.They typically track the direction of the 10-year US Treasury yield, which lenders use as a benchmark for pricing home loans.The 10-year Treasury yield rose to 4.14% at midday Thursday, up from around 4% a week earlier.Treasury yields have moved higher in recent days as rising oil prices added fresh inflation concerns, potentially complicating the Federal Reserve’s plans to cut interest rates.



Source link

Continue Reading

Trending